1. Home
  2. ATYR vs HCAT Comparison

ATYR vs HCAT Comparison

Compare ATYR & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • HCAT
  • Stock Information
  • Founded
  • ATYR 2005
  • HCAT 2008
  • Country
  • ATYR United States
  • HCAT United States
  • Employees
  • ATYR 59
  • HCAT N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • HCAT Computer Software: Programming Data Processing
  • Sector
  • ATYR Health Care
  • HCAT Technology
  • Exchange
  • ATYR Nasdaq
  • HCAT Nasdaq
  • Market Cap
  • ATYR 105.8M
  • HCAT 237.9M
  • IPO Year
  • ATYR 2015
  • HCAT 2019
  • Fundamental
  • Price
  • ATYR $1.03
  • HCAT $2.81
  • Analyst Decision
  • ATYR Buy
  • HCAT Hold
  • Analyst Count
  • ATYR 6
  • HCAT 11
  • Target Price
  • ATYR $8.88
  • HCAT $4.70
  • AVG Volume (30 Days)
  • ATYR 15.6M
  • HCAT 849.1K
  • Earning Date
  • ATYR 11-06-2025
  • HCAT 11-05-2025
  • Dividend Yield
  • ATYR N/A
  • HCAT N/A
  • EPS Growth
  • ATYR N/A
  • HCAT N/A
  • EPS
  • ATYR N/A
  • HCAT N/A
  • Revenue
  • ATYR N/A
  • HCAT $316,093,000.00
  • Revenue This Year
  • ATYR $420.85
  • HCAT $4.52
  • Revenue Next Year
  • ATYR $1,919.44
  • HCAT $0.57
  • P/E Ratio
  • ATYR N/A
  • HCAT N/A
  • Revenue Growth
  • ATYR N/A
  • HCAT 5.55
  • 52 Week Low
  • ATYR $0.97
  • HCAT $2.52
  • 52 Week High
  • ATYR $7.29
  • HCAT $9.24
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 22.25
  • HCAT 34.00
  • Support Level
  • ATYR $1.00
  • HCAT $2.87
  • Resistance Level
  • ATYR $6.50
  • HCAT $3.42
  • Average True Range (ATR)
  • ATYR 0.46
  • HCAT 0.17
  • MACD
  • ATYR -0.51
  • HCAT -0.04
  • Stochastic Oscillator
  • ATYR 1.01
  • HCAT 1.98

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

Share on Social Networks: